FDG-PET/CT在不明显菌血症中的临床价值:针对触酶阴性革兰阳性球菌或金黄色葡萄球菌
本研究回顾性分析157例患者共165次触酶阴性革兰阳性球菌(排除肺炎球菌和肠球菌)或金黄色葡萄球菌菌血症(BUOCSA)发作,评估FDG-PET/CT检测感染灶的能力及临床影响。FDG-PET/CT在56.4%的病例中检出感染灶,47.3%具有高临床影响,41.1%为首次识别感染灶的影像方法,14.7%导致抗菌治疗改变。结论认为FDG-PET/CT在BUOCSA中具有临床实用性,但需前瞻性研究确认。
要点
- FDG-PET/CT在56.4%的BUOCSA病例中检出感染灶。
- 47.3%的病例中FDG-PET/CT具有高临床影响。
- 41.1%的病例中FDG-PET/CT为首次识别感染灶的影像方法。
核心结论
- FDG-PET/CT在BUOCSA中似乎具有临床实用性,但需前瞻性研究确认。
研究设计与样本
- 回顾性识别157例患者共165次BUOCSA发作,均后续接受FDG-PET/CT,数据来自医疗记录。
主要发现
- FDG-PET/CT在56.4%的病例中检出感染灶,47.3%具有高临床影响。
- FDG-PET/CT在41.1%的菌血症病例中为首次识别感染灶的影像方法。
- FDG-PET/CT导致14.7%的病例抗菌治疗改变,9.8%的病例确立与菌血症无关的新诊断。
- 检出率和临床影响不受FDG-PET/CT前抗菌治疗时长、从怀疑菌血症至FDG-PET/CT扫描的天数、菌血症类型或癌症的显著影响。
临床怎么用
- 对于BUOCSA患者,FDG-PET/CT可考虑用于检测感染灶并指导抗菌治疗调整。
局限性
- 本研究为回顾性设计,需前瞻性研究确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Bacteremia is associated with high mortality, especially when the site of infection is unknown. While conventional imaging usually focus on specific body parts, FDG-PET/CT visualizes hypermetabolic foci throughout the body. PURPOSE: To investigate the ability of FDG/PET-CT to detect the site of infection and its clinical impact in bacteremia of unknown origin with catalase-negative Gram-positive cocci (excluding pneumococci and enterococci) or Staphylococcus aureus (BUOCSA). METHODS: We retrospectively identified 157 patients with 165 episodes of BUOCSA, who subsequently underwent FDG-PET/CT. Data were collected from medical records. Decision regarding important sites of infection in patients with bacteremia was based on the entire patient course and served as reference diagnosis for comparison with FDG-PET/CT findings. FDG-PET/CT was considered to have high clinical impact if it correctly revealed site(s) of infection in areas not assessed by other imaging modalities or if other imaging modalities were negative/equivocal in these areas, or if it established a new clinically relevant diagnosis, and/or led to change in antimicrobial treatment. RESULTS: FDG-PET/CT detected sites of infection in 56.4% of cases and had high clinical impact in 47.3%. It was the first imaging modality to identify sites of infection in 41.1% bacteremia cases, led to change of antimicrobial therapy in 14.7%, and established a new diagnosis unrelated to bacteremia in 9.8%. Detection rate and clinical impact were not significantly influenced by duration of antimicrobial treatment preceding FDG-PET/CT, days from suspicion of bacteremia to FDG-PET/CT-scan, type of bacteremia, or cancer. CONCLUSION: FDG-PET/CT appears clinically useful in BUOCSA. Prospective studies are warranted for confirmation.
引用
- Brøndserud MB, Pedersen C, Rosenvinge FS, et al. Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus. Eur J Nucl Med Mol Imaging. 2019. PMID: 30788532. doi:10.1007/s00259-019-04289-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。